{"doi":"10.1007/bf01249283","title":"The contribution of amphetamine metabolites of (?)-deprenyl to its antiparkinsonian properties","abstract":null,"journal":"Journal of Neural Transmission","year":1982,"id":28789,"datarank":3.0186906096774933,"base_score":3.8712010109078907,"endowment":3.8712010109078907,"self_citation_contribution":0.5806801516361837,"citation_network_contribution":2.4380104580413096,"self_endowment_contribution":0.5806801516361837,"citer_contribution":2.4380104580413096,"corpus_percentile":null,"corpus_rank":null,"citation_count":47,"citer_count":44,"citers_with_citation_signal":41,"citers_with_endowment":41,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":160332,"name":"M. Sandler","orcid":null,"position":1,"is_corresponding":false},{"id":160333,"name":"A. J. Lees","orcid":null,"position":2,"is_corresponding":false},{"id":160334,"name":"C. Ward","orcid":null,"position":3,"is_corresponding":false},{"id":160335,"name":"G. M. Stern","orcid":null,"position":4,"is_corresponding":false},{"id":160331,"name":"J. D. Elsworth","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.8712010109078907,"endowment":3.8712010109078907,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"6809891","pmcid":null,"openalex_id":"https://openalex.org/W2027074304","authors":[],"funders":[],"total_grants":0,"fwci":0.5224,"citation_percentile":0.51571497,"influential_citations":1,"citation_trend":[{"year":2015,"count":1},{"year":2016,"count":1},{"year":2019,"count":1},{"year":2021,"count":1}],"oa_status":"closed","license":"http://www.springer.com/tdm","oa_locations":[{"url":"http://link.springer.com/content/pdf/10.1007/BF01249283.pdf","host_type":"publisher"},{"url":"http://link.springer.com/article/10.1007/BF01249283/fulltext.html","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1007/BF01249283","host_type":"publisher"},{"url":"https://doi.org/10.1007/bf01249283","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/6809891","host_type":"repository"},{"url":"http://discovery.ucl.ac.uk/116118/","host_type":"repository"}],"fields_of_study":["Neuroscience and Neuropharmacology Research","Parkinson's Disease Mechanisms and Treatments","Neurotransmitter Receptor Influence on Behavior","Chemistry","Medicine","Amphetamine","Double-Blind Method","Drug Therapy, Combination","Humans","Hydrogen-Ion Concentration","Levodopa","Methamphetamine","Middle Aged","Parkinson Disease","Phenethylamines","Selegiline"],"mesh_terms":["Amphetamine","Double-Blind Method","Drug Therapy, Combination","Humans","Hydrogen-Ion Concentration","Levodopa","Methamphetamine","Middle Aged","Parkinson Disease","Phenethylamines","Selegiline"],"keywords":["Metabolite","Methamphetamine","Amphetamine","Pharmacology","Selegiline","Drug","Active metabolite","Medicine","Chemistry","Parkinson's disease","Internal medicine","Dopamine","Disease"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T22:09:03.298794Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}